AbbVie Inc.
(ABBV : NYQ)
Sector: Healthcare | Industry: Drug Manufacturers - General
$289.08
+6.40 (+2.26%)
MARKET CAP
$510.84B
FCF YIELD
3.30%
CURRENT PRICE
$289.08
P/E RATIO
81.66x
MODEL INPUTS
Intrinsic Fair Value
$96,489.50
per share
5-YEAR FREE CASH FLOW PROJECTIONS
| Year | Projected FCF | Discount Factor (WACC) | Present Value (PV) |
|---|---|---|---|
| Base (0) | $16.87B | - | - |
| Year 1 | $65.86B | at 290.4% growth | $60.42B |
| Year 2 | $257.12B | at 290.4% growth | $216.42B |
| Year 3 | $1.00T | at 290.4% growth | $775.12B |
| Year 4 | $3.92T | at 290.4% growth | $2.78T |
| Year 5 | $15.30T | at 290.4% growth | $9.94T |
VALUATION ARITHMETIC
| Valuation Step | Value |
|---|---|
| PV of Projected FCFs (Sum Y1-Y5) | $13.77T |
| Terminal Value (Perpetuity at 2.5%) | $241.26T |
| PV of Terminal Value | $156.80T |
| Enterprise Value (EV) | $170.57T |
| Less: Total Debt | -$70.88B |
| Add: Total Cash & Equivalents | +$6.57B |
| Equity Value | $170.51T |
| Divided by: Shares Outstanding | 1,767,117,285.00 |
| Intrinsic Value (Fair Value per Share) | $96,489.50 |
FINANCIAL RATIOS & STATS
| Financial Metric | Value |
|---|---|
| Trailing P/E | 81.66x |
| Forward P/E | 17.84x |
| Price-to-Book (P/B) | -86.06x |
| Price-to-Sales (P/S) | 7.93x |
| Net Profit Margin (Net Income / Revenue) | 9.80% |
| Operating Profit Margin (EBIT / Revenue) | 40.03% |
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | 10.51% |
| Dividend Rate | $6.92 |
| Dividend Yield | 2.39% |
| Ex-Dividend Date | 2026-10-15 |
| Next Earnings Date | 2026-10-30 |